11 completed, 5 terminated, 3 unknown, 1 enrolling by invitation. 9 Phase 1, 6 Phase 2, 3 Phase 3, 2 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 6, Terminated 3 |
| Phase 2 | 6 | Unknown 3, Completed 2, Terminated 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Early Phase 1 | 2 | Completed 2 |
| Phase 4 | 1 | Enrolling by invitation 1 |
Follow Iodine-123: new trials by email Literature Review of Iodine-123 trials Research Report on Iodine-123
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery Computed Tomography, Iodine I-123, Planar Imaging - Thyroid Gland Follicular Carcinoma | Terminated | Mayo Clinic | 2 | 2023-11-10 | 2026-08-11 | |
| Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3 SPECT - Primary Breast Cancer | Phase 1 | Completed | Tomsk National Research Medical Center of the Russian Academy of Sciences | 10 | 2023-09-01 | 2026-06-24 |
| MIBG in Aging and Neurologic Disorders meta-iodobenzylguanidine (MIBG) (123I), 123I-MIBG scintigraphy - Lewy Body Disease, Dementia | Phase 4 | Enrolling by invitation | Mayo Clinic | 50 | 2023-05-08 | 2026-07-30 |
| Altropane Dose for Imaging Patients With Suspected Parkinson's Disease Altropane (123I) Injection - Parkinson Disease, Movement Disorders | Phase 2 | Terminated | GE Healthcare | 15 | 2023-04-24 | 2025-07-15 |
| A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers. DaTSCAN™ Ioflupane (123I) Injection - Healthy Subjects (HS) | Phase 1 | Completed | GE Healthcare | 9 | 2021-05-13 | 2023-08-02 |
| Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors 3-[18F]Fluoro-para-hydroxyphenethylguanidine, [123I] metaiodobenzylguanidine, Positron emission tomography/computed tomography scan - Neuroendocrine Tumors | Early Phase 1 | Completed | University of Michigan Rogel Cancer Center | 32 | 2020-10-19 | 2026-06-08 |
| A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD) | Phase 3 | Completed | GE Healthcare | 172 | 2020-06-28 | 2023-10-16 |
| Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology MIBI-Tc99m/Iodine-123 - Malignancy of Thyroid Nodules | Phase 2 / Phase 3 | Completed | Nantes University Hospital | 372 | 2019-01-17 | 2025-06-06 |
| 124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. MIBG label with I123 or I124, SPECT imaging - Parkinson Disease, Neuroendocrine Tumors | Phase 2 | Unknown | Tel-Aviv Sourasky Medical Center | 40 | 2013-08-01 | 2013-08-29 |
| Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer I131, I123 - Thyroid Neoplasms | Phase 2 / Phase 3 | Unknown | National Cancer Center, Korea | 556 | 2013-05-01 | 2017-01-20 |
| Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy Ad5-CMV-NIS, Liothyronine Sodium, Reverse Transcriptase Polymerase Chain Reaction - Prostate Cancer | Phase 1 | Terminated | Mayo Clinic | 8 | 2008-11-03 | 2026-07-22 |
| Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC [123I] MNI-308 - Alzheimer Disease | Phase 1 | Terminated | Molecular NeuroImaging | 2 | 2007-10-01 | 2009-08-21 |
| Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects [123I] AV-151 - Alzheimer Disease | Phase 1 | Completed | Institute for Neurodegenerative Disorders | 20 | 2007-09-01 | 2019-03-14 |
| Development of Cognitive Assessment Tools in Parkinson Disease [123I] IBVM and SPECT imaging, Subjects will undergo the 123-I IBVM imaging visit - Parkinson Disease | Early Phase 1 | Completed | Institute for Neurodegenerative Disorders | 75 | 2007-07-01 | 2012-02-09 |
| Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA Iodine-124, Iodine-123, F-18 FDG - Thyroid Cancer | Withdrawn | Stanford University | 2007-05-01 | 2022-06-21 | ||
| Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls [123-I] AV-83 Injection and Imaging Procedures - Alzheimers Disease | Phase 1 | Completed | Molecular NeuroImaging | 30 | 2007-03-01 | 2008-05-13 |
| Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects [123I] AV 39 - Alzheimers Disease | Phase 1 | Completed | Molecular NeuroImaging | 30 | 2007-02-01 | 2008-04-24 |
| Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients [123I] mZINT injection and serial dynamic SPECT imaging - Parkinson Disease | Phase 1 | Terminated | Institute for Neurodegenerative Disorders | 28 | 2007-01-01 | 2010-10-06 |
| Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO) apomorphine, [(123)I] iodobenzamide - Alcoholism | Phase 2 | Unknown | Hospital Universitari Vall d'Hebron Research Institute | 50 | 2007-01-01 | 2009-04-29 |
| Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease [123I] 5-IA - Parkinson Disease | Phase 2 | Completed | Institute for Neurodegenerative Disorders | 9 | 2006-11-01 | 2014-05-07 |
Showing 20 of 21. Sign in to see all of them.
Parkinson Disease (6) · Alzheimer Disease (5) · Parkinsonian Disorders (3) · Neuroendocrine Tumors (2) · Neurologic Manifestations (2) · Thyroid Neoplasms (2) · Adenocarcinoma, Follicular (1) · Alcoholism (1) · Cognitive Dysfunction (1) · Dementia (1) · Essential Tremor (1) · Lewy Body Disease (1) · Movement Disorders (1) · Multiple System Atrophy (1) · Prostatic Neoplasms (1)
Institute for Neurodegenerative Disorders (5) · GE Healthcare (3) · Mayo Clinic (3) · Molecular NeuroImaging (3) · Hospital Universitari Vall d'Hebron Research Institute (1) · Nantes University Hospital (1) · National Cancer Center, Korea (1) · Stanford University (1) · Tel-Aviv Sourasky Medical Center (1) · Tomsk National Research Medical Center of the Russian Academy of Sciences (1) · University of Michigan Rogel Cancer Center (1)
United States (13) · China (2) · France (1) · Israel (1) · Russia (1) · South Korea (1) · Spain (1)
Danna L Jennings, MD (4) · Danna Jennings, MD (2) · Andrei Iagaru (1) · Biao LI (1) · Bradley Boeve, MD (1) · Brian J. Davis, M.D. (1) · David Raffel, Ph.D. (1) · Einat Even Sapir, PhD, MD (1) · Eun Kyung Lee, M.D.,Ph.D. (1) · Iain Ross McDougall (1) · John P Seibyl, MD (1) · John Seibyl, MD (1) · Jolanta M. Durski, MD (1) · Miquel Casas, Prof (1) · Olga Bragina, Dsc (1)
P50CA091956 (1)